OTS is reliable in predicting paediatric cataract visual outcome

Article

The Ocular Trauma Score (OTS) is a reliable predictor of final visual outcome in children with traumatic cataract

The Ocular Trauma Score (OTS) is a reliable predictor of final visual outcome in children with traumatic cataract, according to a paper featured in the Journal of Cataract and Refractive Surgery.

The retrospective cohort study, led by Dr Mehul A. Shah, Drashti Netralaya, Gujarat, India, included 354 children with traumatic cataract. Each child was examined and reviewed for comorbidities caused by trauma.

Surgery and IOL implantation was performed for each patient and each was treated for amblyopia, if necessary. Six weeks postoperatively all patients were re-examined. Patients were divided into two traumatic cataract groups- open-globe injury and close-globe injury. The OTS was used to predict visual outcomes and the results were compared with outcomes gathered from statistical tests.

In the open-globe group six weeks postoperatively it was found that final corrected distance visual acuity (CDVA) was better than 20/200 in 181 eyes and 20/40 or better in 110 eyes. In the closed-globe group CDVA was better than 20/200 in 36 eyes and 20/40 or better in 15 eyes.

In total, 214 eyes presented with a final CDVA better than 20/200 and 123 eyes had a CDVA of 20/40 or better. This indicated that the OTS is a reliable predictor of the final visual outcome in paediatric patients with traumatic cataract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.